Lipoprotein-associated phospholipase A2: An independent predictor of cardiovascular risk and a novel target for immunomodulation therapy

Cardiology in Review

Volumn 17, Issue 5, 2009, Pages 222-229

  Khakpour, Houman ^a   Frishman, William H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Atherosclerosis; Darapladib; Inflammation; Lipoproteinassociated phospholipase; Lp PLA2

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; DARAPLADIB; FENOFIBRATE; FIBRINOGEN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLATELET ACTIVATING FACTOR INHIBITOR 1; PRAVASTATIN; SB 48048; SIMVASTATIN; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE MARKER; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; GENE FREQUENCY; HUMAN; HYPERLIPIDEMIA; IMMUNOMODULATION; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; VASCULITIS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ENZYME INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 70349146199     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181b2434e     Document Type: Review

References (72)

1. Wilensky RL, Hamamdzic D. The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation. Curr Opin Cardiol. 2007; 22:545-551.
2. Erickson B, Sperber K, Frishman WH. Toll-like receptors: new therapeutic targets for the treatment of atherosclerosis, acute coronary syndromes, and myocardial failure. Cardiol Rev. 2008;16:273-279
3. Riley E, Dasari V, Frishman WH, et al. Vaccines in development to prevent and treat athero-sclerotic disease. Cardiol Rev. 2008;16:288-300.
4. Sporter RJ, Kim JH, Frishman WH. Device-based nonspecific immunomodu-lation therapy (Celecade) and its potential role in the treatment of chronic heart failure. Cardiol Rev. 2008;16:280-287.
5. Weintraub HS. Identifying the vulnerable patient with rupture-prone plaque. Am J Cardiol. 2008;101:3F-10F.
6. Packard CJ, O'Reilly DS, Caslake MJ, et al; West of Scotland Coronary Prevention Study Group. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2000;343: 1148-1155.
7. Koenig W, Khuseyinova N, Lowel H, et al. Lipoprotein-associated phospho-lipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation. 2004;110:1903-1908.
8. Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phos-pholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam study. Circulation. 2005;111:570-575.
9. Daniels LB, Laughlin GA, Sarno MJ, et al. Lipoprotein-associated phospho-lipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the rancho bernardo study. J Am Coll Cardiol. 2008;51:913-919.
10. Blake GJ, Dada N, Fox JC, et al. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol. 2001;38:1302-1306.
11. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phos-pholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. Circulation. 2004;109:837-842.
12. Brilakis ES, McConnell JP, Lennon RJ, et al. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005;26:137-144.
13. Koenig W, Twardella D, Brenner H, et al. Lipoprotein-associated phospho-lipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006;26:1586-1593.
14. Corsetti JP, Rainwater DL, Moss AJ, et al. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarc-tion patients. Clin Chem. 2006;52:1331-1338.
15. Sabatine MS, Morrow DA, O'Donoghue M, et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol. 2007;27:2463-2469.
16. Blankenberg S, Stengel D, Rupprecht HJ, et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res. 2003;44:1381-1386.
17. Khuseyinova N, Imhof A, Rothenbacher D, et al. Association between lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis. 2005;182:181-188.
18. Gerber Y, McConnell JP, Jaffe AS, et al. Lipoprotein-associated phospho-lipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol. 2006;26:2517-2522. (Pubitemid 44607474)
19. Winkler K, Hoffmann MM, Winkelmann BR, et al. Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the ludwigshafen risk and cardiovascular health study). Clin Chem. 2007;53:1440-1447.
20. Schaloske RH, Dennis EA. The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta. 2006;1761:1246-1259.
21. Zalewski A, Macphee C, Nelson JJ. Lipoprotein-associated phospholipase A2: a potential therapeutic target for atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:527-532. (Pubitemid 43008525)
22. Stafforini DM, Tjoelker LW, McCormick SP, et al. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem. 1999;274:7018-7024.
23. Tselepis AD, John Chapman M. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl. 2002;3:57-68.
24. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a che-motactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA. 1988;85:2805-2809.
25. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arte-rioscler Thromb Vasc Biol. 2005;25:923-931. (Pubitemid 40627835)
26. Lavi S, McConnell JP, Rihal CS, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation. 2007;115:2715-2721.
27. Garza CA, Montori VM, McConnell JP, et al. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc. 2007;82:159-165.
28. Dada N, Kim NW, Wolfert RL. Lp-PLA2: an emerging biomarker of coronary heart disease. Expert Rev Mol Diagn. 2002;2:17-22.
29. MacPhee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospho-lipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999;338(pt 2):479-487.
30. Stafforini DM, McIntyre TM, Zimmerman GA, et al. Platelet-activating factor acetylhydrolases. J Biol Chem. 1997;272:17895-17898.
31. Mohler ER III, Ballantyne CM, Davidson MH, et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008;51:1632-1641.
32. Theilmeier G, De Geest B, Van Veldhoven PP, et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/-mice. FASEB J. 2000;14:2032-2039.
33. Quarck R, De Geest B, Stengel D, et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipopro-tein E-deficient mice. Circulation. 2001;103:2495-2500.
34. Tsaoussis V, Vakirtzi-Lemonias C. The mouse plasma PAF acetylhydrolase: II. It consists of two enzymes both associated with the HDL. J Lipid Mediat Cell Signal. 1994;9:317-331.
35. Singh U, Zhong S, Xiong M, et al. Increased plasma nonesterified fatty acids and platelet-activating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice. Clin Sci (Lond). 2004;106:421-432.
36. Shi Y, Zhang P, Zhang L, et al. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis. 2007;191:54-62.
37. Wilensky RL, Shi Y, Mohler ER III, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008;14:1059-1066.
38. Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospho-lipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:2523-2529.
39. Hakkinen T, Luoma JS, Hiltunen MO, et al. Lipoprotein-associated phospho-lipase A(2), platelet-activating factor acetylhydrolase, is expressed by mac-rophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1999;19:2909-2917.
40. Mannheim D, Herrmann J, Versari D, et al. Enhanced expression of lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke. 2008;39:1448-1455.
41. Gorelick PB. Lipoprotein-associated phospholipase and risk of stroke. A2 Am J Cardiol. 2008;101:34F- 40F.
42. Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol. 2008;101:23F-33F.
43. Macphee CH. Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol. 2001;1:121-125.
44. Carpenter KL, Dennis IF, Challis IR, et al. Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidized LDL on human monocyte-macrophages. FEBS Lett. 2001;505:357-363.
45. Ishihara M, Iwasaki T, Nagano M, et al. Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (lp-PLA2) deficiency patients. J Hum Genet. 2004;49:302-307.
46. Yamada Y, Yoshida H, Ichihara S, et al. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis. 2000;150:209-216.
47. Unno N, Nakamura T, Kaneko H, et al. Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in Japan. J Vasc Surg. 2000;32:263-267.
48. Jang Y, Kim OY, Koh SJ, et al. The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men. J Clin Endocrinol Metab. 2006;91: 3521-3527.
49. Kruse S, Mao XQ, Heinzmann A, et al. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet. 2000;66:1522-1530.
50. Abuzeid AM, Hawe E, Humphries SE, et al. Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis. 2003;168:283-288.
51. Ninio E, Tregouet D, Carrier JL, et al. Platelet-activating factor-acetylhydro-lase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum Mol Genet. 2004;13: 1341-1351.
52. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase as a cardiovascular risk A2 marker. Am J Cardiol. 2008;101:41F-50F.
53. Crandall AM, Corson MA. Use of biomarkers to develop treatment strategies for atherosclerosis. Curr Treat Options Cardiovasc Med. 2008;10:304-315.
54. Caslake MJ, Packard CJ, Suckling KE, et al. Lipoprotein-associated phos-pholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000;150:413-419.
55. Hoogeveen RC, Ballantyne CM. PLAC test for identification of individuals at increased risk for coronary heart disease. Expert Rev Mol Diagn. 2005;5:9-14.
56. Sudhir K. Clinical review: lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. J Clin Endocrinol Metab. 2005;90:3100-3105.
57. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phos-pholipase A2, high-sensitivity C-reactive protein, and risk for incident isch-emic stroke in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. Arch Intern Med. 2005;165:2479-2484.
58. O'Donoghue M, Morrow DA, Sabatine MS, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin or atorVastatin evaluation and infection therapy-thrombolysis in myocardial infarction) trial. Circulation. 2006;113:1745-1752.
59. Yang EH, McConnell JP, Lennon RJ, et al. Lipoprotein-associated phospho-lipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol. 2006;26:106-111.
60. Saougos VG, Tambaki AP, Kalogirou M, et al. Differential effect of hypo-lipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol. 2007;27:2236-2243.
61. Schaefer EJ, McNamara JR, Asztalos BF, et al. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol. 2005;95:1025-1032.
62. Albert MA, Glynn RJ, Wolfert RL, et al. The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Atherosclerosis. 2005;182: 193-198.
63. Rosenson RS. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. Am Heart J. 2008;155:499.e9 - 499.e16.
64. GlaxoSmithKline. Available at: http://www.gsk.com/investors/product- pipeline/pp.htm. Accessed May 3, 2008.
65. Blackie JA, Bloomer JC, Brown MJ, et al. The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospho-lipase A2. Bioorg Med Chem Lett. 2003;13:1067-1070.
66. Serruys PW, Garcia-Garcia HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008;118:1172-1182.
67. The stabilization of atherosclerotic plaque by initiation of darapladib therapy trial (STABILITY). 2008. Available at: http://clinicaltrials.gov/ct2/ show/NCT00799903. Accessed December 15, 2008.
68. Myerson M. Role of lipoprotein-associated phospholipase A2 in predicting risk of cardiovascular disease. Mayo Clin Proc. 2007;82:888; author reply 888-889.
69. Manolio T. Novel risk markers and clinical practice. N Engl J Med. 2003; 349:1587-1589.
70. Khuseyinova N, Greven S, Ruckerl R, et al. Variability of serial lipoprotein-associated phospholipase A2 measurements in postmyocardial infarction patients: results from the AIRGENE study center Augsburg. Clin Chem. 2008;54:124-130.
71. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393. (Pubitemid 36159355)
72. Koenig W. Treating residual cardiovascular risk: will lipoprotein-associated phospholipase A2 inhibition live up to its promise? J Am Coll Cardiol. 2008;51:1642-1644.